Navigation Links
Verenium Corporation to Announce First Quarter 2013 Financial Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release first quarter 2013 financial results on Thursday, May 9, 2013 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Thursday, May 9, 2013 at 5:00 p.m. ET.

(Logo:  http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

The call may be accessed by dialing (877) 755-7422 (domestic) or (678) 894-3067 (international) five minutes prior to start time and providing the passcode 53245436.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at http://ir.verenium.com/.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's ability to develop and/or commercialize its products, diversify its product portfolio, enhance its manufacturing capabilities, capture near-ter
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012
2. Verenium Announces Preliminary Financial Results For Fiscal 2012
3. Verenium To Present At The 25Th Annual Roth Conference
4. Verenium Appoints Holger Liepmann To Its Board Of Directors
5. Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
6. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
7. Verenium Announces $22.5 Million, Five-Year Secured Financing
8. Verenium Corporation To Announce Third Quarter 2012 Financial Results
9. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
10. Verenium Corporation To Announce Second Quarter 2012 Financial Results
11. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences announced ... research and development agreement (CRADA) with Aratana Therapeutics ... development of TRB-N0224 for the treatment and control ... and cats.  Traverse Biosciences has also granted Aratana ... treatment and control of periodontal disease in companion ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
(Date:5/4/2015)... MA (PRWEB) May 04, 2015 ... for drug discovery and life science research, today ... , the latest version of its enterprise solution ... biopharma R&D enables more efficient discovery and development ... approach to integrate and address protein optimization and ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12
... GLASGOW, Scotland, Sept. 3 Leading neurosurgical ... in neurosurgical,diagnostic and treatment devices, along with ... and efficient at the European,Association of Neurosurgical ... than 1,000 neurosurgeons and related medical professionals,will ...
... PARIS, September 2 Sanofi-aventis announced,today that ... 25 and STEEPLE,studies confirm clear net clinical ... infarction (STEMI) for Lovenox(R) vs,Unfractionnated Heparin (UFH). ... year results were presented during,hotline sessions at ...
... Standards and Technology (NIST) have developed two ... validate the performance of analytic instruments that ... Recent years have seen a significant increase ... analytic techniques. Researchers can detect, measure and ...
Cached Biology Technology:Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... designated FV-100, which could alleviate the suffering of millions of ... stage of clinical testing in patients. Developed and ... clinical trial with FV-100 has recently been initiated in America. ... to 10,000 times more potent than existing treatments in early ...
... international team of scientists has proposed a set of ... reefs from ultimate destruction. Their proposal is being ... Indonesia, where leaders of six regional governments plus Australia ... largest-ever marine reserve in world history, the Coral Triangle ...
... the world,s second largest fish hide out for ... online on May 7th in Current Biology , ... of the iconic species and highlights just how little ... animals, the researchers said. "While commonly sighted in ...
Cached Biology News:Clinical trials for shingles drug take an important step forward 2Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Disappearing act of world's second largest fish explained 2
... L sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental ... 3 minutes after turn-on. ... ... ...
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
APG5 autophagy 5-like (S. cerevisiae)...
Biology Products: